Oncology
Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery
January 4, 2024Research and Development BridGene Biosciences, Galapagos, Oncology, drug discovery, oncology
Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration and licensing agreement for the …
Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager
January 2, 2024Research and Development Astellas, Cancer, Elpiscience, Oncology, bispecific macrophage
Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration and license agreement for novel …
Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics
December 20, 2023Research and Development AI diagnostics, Cancer, MSD, Merck, Oncology, Owkin
Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a …
Elekta and BMS partner for digital treatment for melanoma
December 19, 2023Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …
GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment
December 18, 2023Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer
GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …
First patient dosed in Cullinan Oncology’s phase 1 trial for CLN-617
December 15, 2023Research and Development Cullinan Oncology, Oncology, clinical trial, tumours
Cullinan Oncology has announced that the first patient has been dosed with CLN-617 in its phase 1 clinical trial, designed …
Merck and Moderna initiate phase 3 study of NSCLC treatment
December 13, 2023Medical Communications Merck, Moderna, NSCLC, Oncology, clinical trial
Merck (known as MSD outside of the US and Canada) and Moderna have announced the initiation of the phase 3 …
EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma
December 12, 2023Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma
Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …
GSK’s Jemperli approved in EU as treatment for endometrial cancer
December 11, 2023Medical Communications EU, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced that the European Commission (EC) has granted marketing authorisation to Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy, …
Daiichi Sankyo shares results for Ezharmia as lymphoma treatment
December 11, 2023Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma
Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …
Regeneron shares data for multiple myeloma treatment
December 8, 2023Medical Communications Cancer, Oncology, Regeneron, clinical trial
Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …
ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development
December 7, 2023Research and Development NAYA Biosciences, NK cell therapies, ONK Therapeutics, Oncology, partnership
ONK Therapeutics and NAYA Biosciences have announced that they have entered into a research partnership to assess combination therapies consisting …
Genentech shares positive results from phase 3 trial for breast cancer treatment
December 5, 2023Research and Development Genentech, Oncology, breast cancer, oncology
Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …
Dr Stefano Gulià appointed as chief scientific officer of Kling Bio
December 5, 2023Business Services Kling Bio, Oncology, appointment, chief scientific officer
Kling Bio has announced the appointment of Dr Stefano Gulià as chief scientific officer. Dr Gulià has over 15 years …
Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment
December 4, 2023Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …
Latest content
FibroFind appoints Lee Borthwick as CEO
